GW Pharma revenues rise but 1st-qtr loss incurred

5 February 2014

Shares of UK-based cannabis-based drug developer GW Pharmaceuticals (AIM: GWP) fell 3,9% to 287.39 pence this morning, after it announced financial results for its first fiscal quarter ended December 31, 2013, posting a net loss of £2.8 million ($4.7 million) compared to a profit after tax of £2.1 million for the like 2012 period.

Total revenue for the three months leapt 44% to £7.5 million ($12.4 million) compared to £5.2 million. Cash and cash equivalents as at December 31, 2013, were of £35.3 million compared to £38.1 million as at September 30, 2013. Since the period end, this cash position has been further enhanced by receipt of the net proceeds after expenses from the follow-on offering of ADSs on the Nasdaq Global Market of $94.0 million in January 2014. GW’s shares have rocketed some 380% since listing on the Nasdaq last May.

Recent operation highlights

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK